Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from biotechnology

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of…

AAP

KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market

ZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that its KrystoLens, the single-use neuro-endoscope, has officially received certification from the Taiwan Food and Drug Administration (TFDA), marking an important milestone in the company's development in medical imaging and endoscopic applications.

AAP

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test

SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals....

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni

MarketBeat

Manish Singh's View of Oncology Innovation Through Clinical Insight and Long-Term Thinking

Dr. Singh's professional journey spans scientific research, venture investing, and biotechnology leadership, experiences that collectively shaped his perspective on how meaningful innovation occurs.

International Business Times

Biotech startup StrainX Bioworks raises $13 million from Prime Venture, Leo Capital, others

StrainX Bioworks, a synthetic biology and precision fermentation startup, has raised $13 million to advance its biotechnology platform. The company, with a team of over 100 experts, aims to scale production to 100,000 litres and forge global partnerships, positioning India as a leader in biological manufacturing.

The Economic Times

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

AAP

Read news from The Economist, FT, and more,
with one subscription

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study,…

AAP

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

MarketBeat

Why do some high performers still end up earning less than their peers?

In the workplace, it's common to think that diligence directly translates to a fatter paycheck. Yet, the reality is more complex; some top performers find themselves earning less than their underperforming peers. This inequity not only breeds frustration but also undermines loyalty. With companies shrouding their compensation structures in mystery,…

The Economic Times

Celcuity Q1 Earnings Call Highlights

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer. On the company

MarketBeat

Peptide Nasal Spray: Do Nasal Spray Peptides Work?

The world of biotechnology is constantly evolving, seeking ways to make advanced treatments more accessible and less invasive. For many years, the only way to effectively administer peptides was through subcutaneous injections. However, the rise of the peptide nasal spray has changed the conversation entirely. This delivery method offers a…

inkl

PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs. On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank

MarketBeat

Indian-origin biotech engineer admits exposing himself on Emirates flight to UK

An Indian-origin biotechnology engineer has admitted committing an act outraging public decency after allegedly exposing himself during an Emirates flight from Dubai to the UK, according to Daily Mail.

The Times of India

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

France to raise tuition fees for non-EU students from 2026-27

France will implement higher tuition fees for most non-EU students starting in the 2026-27 academic year, with bachelor's programs costing €2,895 and master's degrees €3,941 annually. This policy shift, making differentiated fees the rule and exemptions the exception, aims to reshape international student recruitment, prioritizing fields like AI and biotechnology.

inkl

Anti-Aging Expert Olena Davydova on the Breakthroughs Shaping the Aesthetics Industry in 2026

The era of heavy surgical intervention is gradually giving way to the precision tools of biotechnology and artificial intelligence. We are entering a new phase in the aesthetics industry – one where the goal is no longer to correct visible flaws, but to preserve and support youthful skin at the…

The Conversation

Gene editing in Indonesia: can new biotechnology solve old agricultural problems?

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting its extraordinary biodiversity.

Barchart

Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag?

Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes. Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.”...

Get all your
news in one place.

100's of premium titles.
One news app.

LiveScience

'Stop and re-check everything': Scientists discover 26 new bacterial species in NASA's cleanrooms

Scientists discover 26 new bacterial species in NASA cleanrooms, revealing surprisingly resilient microbes with potential uses in biotechnology and medicine.

Benzinga

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).

Barchart

Bio-Techne Stock: Is Wall Street Bullish or Bearish?

Despite underperforming the broader market and biotechnology industry over the past year, analysts remain strongly bullish on Bio-Techne’s longer-term prospects.

International Business Times

Colossal Biosciences Update: Lab That Brought Back Dire Wolf Buys Pet-Cloning Company

Colossal Biosciences, the Dallas-based biotechnology company known for its bold mission to resurrect extinct species such as the woolly mammoth and the dodo, announced its first-ever acquisition today: ViaGen Pets & Equine, a Texas company specializing in animal cloning and genetic preservation.

Benzinga

Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial

Kura Oncology, Inc. (NASDAQ:KURA) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.

Benzinga

Genenta Extends Collaboration With Anemocyte To Boost Off-The-Shelf Genetic Therapy Production

Genenta Science (NASDAQ:GNTA) shares traded higher in Friday's premarket after the company unveiled an expanded collaboration with biotechnology firm ANEMOCYTE.

Benzinga

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update.

1 2 3 4 5

People

Brian Sullivan

13 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Australian Research Council

Harvard Business School

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.